tiprankstipranks
Advaxis (ADXS)
OTHER OTC:ADXS

Advaxis (ADXS) AI Stock Analysis

Compare
838 Followers

Top Page

AD

Advaxis

(OTC:ADXS)

20Underperform
Advaxis faces substantial financial and operational challenges. The severe decline in revenues and persistent losses, coupled with technical indicators pointing to further downside risk, contribute to a low overall score. Valuation metrics are unhelpful due to negative earnings, and the drastic stock price drop post-earnings suggests investor pessimism.

Advaxis (ADXS) vs. S&P 500 (SPY)

Advaxis Business Overview & Revenue Model

Company DescriptionAdvaxis, Inc. (ADXS) is a biotechnology company focused on the development and commercialization of immunotherapies based on its proprietary Lm platform technology. This platform uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate the immune system to elicit an anti-tumor response. The company's core products aim to address unmet medical needs in oncology, with a pipeline that includes therapies for various cancers such as cervical, head and neck, and prostate cancers.
How the Company Makes MoneyAdvaxis primarily generates revenue through collaborative research and development agreements, as well as licensing deals with other biotechnology and pharmaceutical companies. These collaborations often involve upfront payments, milestone payments, and potential royalties on sales if the partnered products reach commercialization. Another potential revenue stream includes government grants or funding that support research and development activities. Significant partnerships and collaborations with industry players also contribute to its financial prospects by providing resources and shared expertise to advance its pipeline.

Advaxis Financial Statement Overview

Summary
Advaxis is experiencing severe financial challenges, with a dramatic decline in revenues, persistent losses, and a troubled balance sheet. The negative equity and cash flow deficits signal significant financial distress.
Income Statement
15
Very Negative
Advaxis has faced significant challenges on its income statement, with total revenue declining dramatically from $20.88 million in 2019 to just $13,000 in 2023. The company has consistently reported negative EBIT and net income, indicating persistent operational losses. The net profit margin is severely negative, highlighting profitability issues. The revenue growth rate has also been negative, reflecting a downward trend in sales.
Balance Sheet
10
Very Negative
The balance sheet indicates financial distress, with stockholders' equity turning negative by 2023, reflecting a substantial erosion of capital. The debt-to-equity ratio is not applicable due to negative equity, but total liabilities exceed total assets, indicating insolvency. Return on equity is deeply negative, further demonstrating financial instability.
Cash Flow
20
Very Negative
The cash flow statement reveals negative operating cash flow across all periods, with substantial free cash flow deficits indicating cash burn. However, recent financing activities have provided some liquidity, as reflected in the positive financing cash flow. The ratios of operating and free cash flow to net income are negative, highlighting cash flow challenges.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
13.00K250.00K3.24M253.00K2.33M
Gross Profit
0.00-64.00K-468.00K-1.03M1.05M
EBIT
-36.27M-16.09M-18.79M-26.45M-17.71M
EBITDA
-35.87M-15.78M-18.77M-24.39M-17.56M
Net Income Common Stockholders
-48.07M-14.36M-17.86M-26.47M-17.79M
Balance SheetCash, Cash Equivalents and Short-Term Investments
4.88M25.21M41.61M25.18M16.73M
Total Assets
16.58M25.93M46.78M38.53M20.05M
Total Debt
8.32M12.00K40.00K6.02M299.00K
Net Debt
3.43M-25.20M-41.57M-19.16M-16.43M
Total Liabilities
41.00M2.30M7.89M8.35M5.60M
Stockholders Equity
-24.42M23.63M38.89M30.18M14.45M
Cash FlowFree Cash Flow
-29.48M-15.48M-15.90M-22.69M-16.28M
Operating Cash Flow
-29.48M-15.28M-15.44M-21.94M-14.95M
Investing Cash Flow
5.95M-166.00K-11.00K-748.00K-1.58M
Financing Cash Flow
26.00M-956.00K31.89M15.50M7.08M

Advaxis Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.03
Price Trends
50DMA
0.03
Negative
100DMA
0.04
Negative
200DMA
0.10
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
44.60
Neutral
STOCH
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADXS, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.60 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADXS.

Advaxis Risk Analysis

Advaxis disclosed 58 risk factors in its most recent earnings report. Advaxis reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Advaxis Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$665.63M-65.04%41184.20%6.44%
49
Neutral
$6.84B0.05-53.14%2.48%24.49%-3.26%
44
Neutral
$413.18M-58.54%-47.28%
43
Neutral
$1.41B-26.84%1.99%15.95%
37
Underperform
$5.82M-139.80%-100.00%76.13%
20
Underperform
$1.28M197.20%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ADXS
Advaxis
0.03
-0.64
-95.52%
CLDX
Celldex
20.14
-22.38
-52.63%
CRMD
Cormedix
10.38
6.20
148.33%
ALDX
Aldeyra Therapeutics
6.81
4.04
145.85%
SNGX
Soligenix
2.30
-7.89
-77.43%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.